Two layers define every breast implant: a silicone elastomer shell on the outside and a filling on the inside. Saline, silicone gel, cohesive gel, and structured devices all share that same medical-grade outer envelope, while the inner fill decides weight, movement, and rupture behavior. Knowing those two layers turns marketing terms like “gummy bear” and “structured” into specific material facts you can weigh in a consultation.
This breakdown walks through the shell, the four main fills, and how each choice plays out in safety, longevity, and lifestyle fit. Your goal is to walk into a consultation understanding exactly what each device is, what it does, and how its material lines up with your body and your priorities.
Every Implant Starts With a Silicone Elastomer Shell
Pick up any FDA-approved breast implant, and the outer layer belongs to the same family: medical-grade silicone elastomer, a vulcanized (heat-cured) polymer that behaves like firm rubber. Picture the shell as the tire and the filler as the air inside; the tire decides shape and puncture resistance, while the air decides feel.
That shell is typically built in three to five thin layers of silicone elastomer, plus a barrier coat designed to slow filler bleed (slow gel seepage through an intact shell over years). Allergan, Mentor, and Sientra each manufacture these multi-layer shells to proprietary specs, yet they share the same core chemistry. The shell also carries a smooth or textured surface finish, and that finish changes how your surrounding tissue responds.
Smooth vs. Textured Surfaces
A smooth shell slips freely inside the tissue pocket, letting the implant move with your body the way natural breast tissue shifts when you lie down or reach overhead. A textured shell, with a micro-rough or macro-rough surface, was originally designed to grip tissue and stay in a fixed position, which surgeons hoped would lower capsular contracture (painful hardening of the scar capsule around the implant).
Early clinical data suggested texture modestly lowered contracture, especially in subglandular (over-the-muscle) placement, but the benefit came with a separate complication. Macro-textured shells, and to a smaller extent micro-textured ones, have been linked to breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), a rare immune-cell cancer of the scar capsule. The FDA asked Allergan to recall its Biocell textured devices in 2019, and most surgeons now default to smooth shells for routine augmentation.
Polyurethane Foam: A Niche Third Option
A small subset of implants, most notably Polyurethane-coated devices sold outside the U.S. and historically used in revision surgery, adds a thin foam layer over the silicone shell. The foam encourages tissue ingrowth, anchoring the implant aggressively and lowering capsular contracture rates in high-risk patients. Removal later is far harder, which keeps polyurethane-coated implants a specialty tool rather than a mainstream choice.
Quick reference: The shell is silicone elastomer in every case, the surface is usually smooth in current U.S. practice, and foam coatings are reserved for specific revision scenarios.
Inside the Shell: The Fill Materials That Define Each Implant Type
The fill is where implant types diverge most, and where your consultation conversation will probably spend most of its time. Each fill carries a different weight, feel, incision size, and rupture behavior, so the material inside matters as much as the shell around it.
| Fill Type | What’s Inside | Typical Feel | Rupture Behavior |
|---|---|---|---|
| Saline | Sterile saltwater | Firm, water-balloon-like | Body absorbs fluid; implant deflates within hours |
| Traditional silicone gel | Viscous silicone polymer | Soft, natural, breast-like | Gel stays in or near shell; “silent rupture” possible |
| Cohesive gel (“gummy bear”) | Higher cross-linked silicone gel | Firmer, shape-holding, stable | Gel holds form; minimal migration if shell fails |
| Structured / hybrid | Saline in internal chambers with baffles | Soft with structure, less slosh | Same as saline; folds naturally; leak visible |
Saline: Sterile Saltwater Added After Insertion
Saline implants arrive empty, folded tightly so the surgeon can place them through an incision of roughly 3 cm, then fill them with sterile salt water once positioned. That smaller incision is saline’s biggest practical advantage, and fill volume can be fine-tuned in the operating room for symmetry. The trade-off is feel: saline is heavier per volume than gel and tends to feel firmer, especially when natural tissue coverage is thin.
If a saline shell ruptures, the saltwater is harmlessly absorbed and the implant visibly deflates within hours, which is why saline is often recommended when immediate confirmation of failure matters more than subtle feel.
Traditional Silicone Gel: The Soft, Natural Feel
Silicone gel implants come prefilled with a thick, sticky polymer of cross-linked (chemically bonded into a network) polydimethylsiloxane chains. The viscosity (how thick and flow-resistant a fluid is) of that gel gives silicone its reputation for feeling closest to natural breast tissue, soft with subtle movement, without the slosh of saline. In a rupture, the viscous gel tends to stay within the fibrous capsule your body forms around the device rather than migrating into tissue.
Cohesive Gel and “Gummy Bear” Implants
Cohesive gel pushes silicone gel further: polymer chains are more densely cross-linked, so the gel behaves more like a soft solid than a liquid. Cut a highly cohesive gel implant in half and the filling holds its shape, much like a gummy bear candy, which is where the nickname comes from. That structural stability is the central safety claim; if the shell fails, the gel stays put, rupture is easier to spot on imaging, and tissue migration drops dramatically.
Most cohesive gel implants are also form-stable, holding a teardrop shape rather than rounding out under gravity. Shape stability gives surgeons more control over the breast contour, particularly for reconstruction after mastectomy, though it requires a textured shell to prevent rotation in the pocket.
Structured and Hybrid Implants: Combining the Best of Both
Structured implants, best known by the brand name IDEAL IMPLANT, use a silicone elastomer shell with internal chambers and baffles filled with saline. The nested chambers control how the saline moves, reducing the sloshing sensation while keeping the safety profile of a saline fill: rupture leads to visible deflation and harmless absorption. Similar hybrid designs, like Motiva’s SmoothSilk and Ergonomix lines, layer silicone gel over a saline chamber or use a softer gel formulation to balance feel and shape retention.
Because once the shell is chosen, the fill is what determines how the implant actually feels and behaves inside the body.
Match the fill to your priority: saline and structured implants for visible rupture detection, silicone gel for the softest feel, cohesive gel for shape control and migration resistance.
How Shell Texture and Gel Cohesivity Shape Real-World Performance
Once you know the shell and fill, the next layer is how those materials behave inside your body over years, and that is where texture and gel thickness earn their keep. Two women with similar anatomy can have very different long-term outcomes based purely on whether their implant is smooth or textured and how cohesive the gel inside is.
Smooth shells move freely in the pocket, which most patients prefer cosmetically, and current data shows comparable capsular contracture rates to texture when the implant sits under the muscle. Textured shells, after the BIA-ALCL association emerged, are now used selectively, mainly for shaped cohesive gel implants that need to lock in place to keep their teardrop contour. Gel cohesivity is a quieter safety upgrade: a more cross-linked gel stays where it sits, making rupture easier to spot on MRI and keeping silicone out of your lymph nodes if the shell ever fails.
The BIA-ALCL Connection to Textured Shells
BIA-ALCL is a T-cell lymphoma, not breast cancer, that grows in the fluid or scar capsule around a textured implant, typically appearing years after surgery as persistent swelling or a palpable mass. The FDA’s most recent update puts lifetime risk for textured implants in the range of roughly 1 in 3,000 to 1 in 30,000 depending on texture grade, with most cases successfully treated by removing the implant and surrounding capsule. The risk is rare enough that current FDA guidance does not recommend prophylactic (preventive) removal, but it has pushed the field strongly toward smooth shells for primary augmentation.
Why Gel Cohesivity Matters When a Shell Fails
Older, less cohesive silicone gel could migrate several centimeters from a ruptured shell, making cleanup in revision surgery difficult and sometimes leaving residual silicone in tissue planes. Highly cohesive gel largely stays inside the capsule, so a surgeon can remove the device and capsule cleanly. That same property makes rupture easier to detect on imaging: the gel holds shape, producing clearer contrast between intact and ruptured areas on MRI.
Those performance characteristics become clinically meaningless, however, if regulators never cleared the device in the first place.
FDA Approval Status and the Generations of Silicone Implants
Regulatory history matters because it explains why silicone implants were off the U.S. augmentation market for most of the 1990s and what changed when they came back. The story also clarifies which manufacturers you are actually choosing between today.
The 1992 Restriction and 2006 Re-Approval
In 1992, the FDA restricted silicone gel implants to reconstruction and revision patients, citing concerns about silent rupture and the difficulty of detecting gel that had migrated outside the shell. Over the next fourteen years, manufacturers ran large prospective studies, and the data ultimately showed no link between silicone gel implants and systemic diseases like connective tissue disorders or breast cancer. Based on that evidence, the FDA re-approved silicone gel implants for cosmetic augmentation in November 2006, conditional on continued post-approval studies tracking rupture rates and long-term outcomes.
The Three FDA-Approved Manufacturers
Three companies hold FDA approval for breast implants sold in the U.S.: Allergan (now part of AbbVie, marketing under the Natrelle and MemoryGel lines), Mentor (a Johnson & Johnson company), and Sientra, which sells exclusively through board-certified plastic surgeons. Each offers saline, silicone gel, and cohesive gel options across multiple profiles and projections, and each is required by the FDA to maintain long-term patient registries that track outcomes.
Age Restrictions: 22 for Augmentation, Any Age for Reconstruction
The FDA’s current labeling makes a clear age split: saline implants are approved for augmentation in patients 18 and older, while silicone gel implants are approved for augmentation in patients 22 and older. Both types are approved for breast reconstruction at any age, including after mastectomy or for congenital asymmetry, because the risk-benefit calculation differs when the alternative is no breast at all.
Longevity, Rupture Rates, and When Replacement Becomes Likely
No implant lasts forever, and material choice strongly affects how you will know when one has reached the end of its useful life. Replacement is a matter of when, not if, so understanding rupture behavior by material is part of the decision.
Modern implants carry published rupture rates of roughly 1% per year for silicone gel devices and slightly higher early failure rates for saline (around 2–3% in the first few years, dropping thereafter). After 10 years, that math puts the cumulative rupture rate for silicone in the neighborhood of 10–15%, which is why surgeons describe a 10- to 20-year replacement window as a planning benchmark rather than a guarantee.
Silent Rupture vs. Visible Deflation
Silicone gel ruptures are often “silent,” meaning the gel stays inside the capsule and there are no outward symptoms. That is why the FDA recommends MRI or high-resolution ultrasound screening three years after a silicone augmentation and every two years thereafter, a cost and scheduling commitment that does not apply to saline. Saline ruptures are typically self-evident: the implant visibly deflates over hours or days, the saltwater is harmlessly reabsorbed, and most patients simply book replacement when they notice the change.
Material Choice and Screening Logistics
If your priority is minimal follow-up imaging, saline or structured implants remove the MRI screening requirement because any rupture announces itself. If your priority is the softest feel and you accept routine imaging, silicone gel or cohesive gel are the standard picks. Many surgeons now lean toward ultrasound as a cheaper, radiation-free alternative to MRI for monitoring silicone implants, yet MRI remains the gold standard for definitive evaluation.
Plan on replacement roughly every 10–20 years, and pick your screening routine around your fill material, not the other way around.
Matching Implant Materials to Body Type, Lifestyle, and Priorities
Material decisions do not happen in a vacuum; they happen in the context of your anatomy, your activities, and what you want to feel and see. Translating the material science into a personal choice usually comes down to three priorities: feel, safety logistics, and lifestyle fit.
Athletic Patients and Easier Rupture Detection
Runners, CrossFit athletes, and contact-sport participants sometimes prefer saline or structured implants because any rupture is immediately visible, no imaging required, and the device can be replaced on a planned schedule. Highly cohesive gel also appeals to athletes because the form-stable gel will not shift or fold visibly during high-impact movement, which matters if you have low body fat and minimal soft tissue coverage.
Feel-First Patients and Silicone Gel
Patients with little natural breast tissue, or those who simply want the most realistic hand feel, frequently select silicone gel or cohesive gel despite the required MRI monitoring. The softer drape and more natural movement under the skin are the trade for committing to imaging, and most patients find the screening schedule manageable once it becomes routine.
Breast Implant Illness and What Materials Can and Can’t Explain
Breast Implant Illness (BII) is an umbrella term patients use for systemic symptoms, including fatigue, joint pain, brain fog, and autoimmune-like reactions, that some women associate with their implants. Large epidemiological studies have not identified a consistent link between silicone material and autoimmune disease, and BII is not currently a recognized medical diagnosis. That does not mean symptoms are not real; some patients report dramatic improvement after explant (implant removal), and the FDA continues to fund research into the mechanisms. Material alone, whether silicone, saline, or cohesive gel, does not currently explain reported systemic symptoms, so the choice of fill is unlikely to be a definitive BII prevention strategy on its own.
A Practical Decision Framework
When you sit down with your surgeon, the conversation usually resolves into three priorities and a clean trade-off.
- Feel priority: Silicone gel or cohesive gel for the softest, most natural drape.
- Safety priority: Cohesive gel for migration resistance, plus a smooth shell to avoid BIA-ALCL risk.
- Lifestyle priority: Saline or structured implants for visible rupture detection and no MRI screening.
- Reconstruction priority: Cohesive gel with a shaped profile for mastectomy reconstruction at any age.
- Athletic priority: Cohesive gel or structured saline for stability during high-impact activity.
The right answer is whichever trade-off you can live with for the next 10–20 years, because the device you choose today is the one you will be monitoring for the foreseeable future.
That long monitoring window is exactly why the final decision deserves a clear-eyed summary of every trade-off.
The Big Picture
The clearest takeaway is that every breast implant is a silicone elastomer envelope around a fill, and your real choice is which fill and which surface. Smooth-shelled cohesive gel devices have quietly become the modern default for augmentation, balancing natural feel, structural stability, and a strong safety profile, while saline and structured implants remain the right pick for patients who want self-evident rupture detection. Walk into your consultation knowing the shell is universal, the fill is the decision, and the FDA-approved manufacturer list is short and well-tracked.
FAQ
What materials are used inside breast implants?
The two main fills are sterile saline (saltwater) and medical-grade silicone gel. Cohesive gel is a higher cross-linked silicone formulation that holds its shape, and structured implants use saline in internal chambers for a softer feel.
Are silicone breast implants safe?
Yes. FDA-approved silicone gel implants have been studied in large prospective trials, and no link has been confirmed to systemic diseases such as autoimmune disorders or breast cancer. Routine MRI or ultrasound screening is recommended to detect silent rupture.
What is the difference between saline and silicone gel implants?
Saline implants are filled after insertion with sterile saltwater, allow smaller incisions, and deflate visibly if they rupture. Silicone gel implants come prefilled, feel softer and more natural, and require imaging to detect silent rupture.
What is the shell of a breast implant made of?
A medical-grade, vulcanized silicone elastomer, functioning like firm rubber, forms the outer shell of every FDA-approved breast implant. The shell may have a smooth or textured surface and is built in multiple layers with a barrier coat.
How long do breast implant materials last?
Modern implants are not lifetime devices. Published rupture rates run roughly 1% per year for silicone gel and slightly higher for saline, which translates into a typical replacement window of 10–20 years for most patients.
Can breast implant materials cause health problems?
Large studies have not linked silicone material to systemic disease, but textured shells have been associated with a rare lymphoma called BIA-ALCL. Textured implants were largely withdrawn from the U.S. market, and smooth-shelled devices are now the standard for primary augmentation.
